


DCC-3116

## Chemical Properties

CAS No. : 2543673-19-2  
 Formula: C<sub>26</sub>H<sub>36</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>  
 Molecular Weight: 535.61  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

|               |   |
|---------------|---|
| Description   | DCC-3116 is an orally active, selective and potent ULK1/2 inhibitor with anticancer activity. DCC-3116 inhibits autophagy and can be used in cancer research.   |
| Targets(IC50) | Autophagy, Ras, Kras  |
| In vitro      | 100 nM DCC-3116 alone inhibited NCI-H2122 and Calu-1 cell proliferation and reduced pS318-ATG13 expression, and DCC-3116 in combination with sotorasib showed synergistic inhibition of human lung cancer cell proliferation driven by the KRAS G12C mutation in vitro. [1] |
| In vivo       | Daily oral or intraperitoneal administration of 3 or 30 mg/kg DCC-3116 for 56 consecutive days alone or in combination with Sotorasib inhibited tumor growth in a mouse model of NSCLC lung cancer. [1]   |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | DMSO: 150 mg/mL (280.05 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+90% Saline: 10 mg/mL (18.67 mM), Suspension.<br>10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.16 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | <b>1mg</b> | <b>5mg</b> | <b>10mg</b> |
|-------|------------|------------|-------------|
| 1 mM  | 1.867 mL   | 9.3352 mL  | 18.6703 mL  |
| 5 mM  | 0.3734 mL  | 1.867 mL   | 3.7341 mL   |
| 10 mM | 0.1867 mL  | 0.9335 mL  | 1.867 mL    |
| 50 mM | 0.0373 mL  | 0.1867 mL  | 0.3734 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Jun 17:2024.02.06.579200.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481